Polymerase acidic protein · SINGLE PROTEIN · Influenza B virus (strain B/Lee/1940)
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Polymerase acidic protein shows approved-linked disease relevance led by influenza. 4 more disease programs remain visible in the same review block. 2 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q9QLI9. Start with influenza, then reuse UniProt Q9QLI9 as the stable protein anchor across project notes and exports.
Start with influenza, then reuse UniProt Q9QLI9 as the stable protein anchor across project notes and exports.
Polymerase acidic protein shows approved-linked disease relevance led by influenza. 4 more disease programs remain visible in the same review block. 2 linked drugs remain visible in the same block.
Start review with influenza because it currently carries approved-linked support. Linked drugs include BALOXAVIR, BALOXAVIR MARBOXIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyPolymerase acidic protein
Review this target as Polymerase acidic protein, mapped to UniProt Q9QLI9. Sequence length is 726 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Polymerase acidic protein as ChEMBL target CHEMBL2028641, mapped to UniProt Q9QLI9. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Polymerase acidic protein is the right protein anchor across sources, using UniProt Q9QLI9 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why influenza is currently framed as approved-linked support. It currently carries 2 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Polymerase acidic protein |
| Target Type | SINGLE PROTEIN |
| Organism | Influenza B virus (strain B/Lee/1940) |
| UniProt | Q9QLI9 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Polymerase acidic protein |
| UniProt Accession | Q9QLI9 |
| Component Type | Protein |
| Sequence Length | 726 aa |
Polymerase acidic protein
Review this target as Polymerase acidic protein, mapped to UniProt Q9QLI9. Sequence length is 726 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Polymerase acidic protein shows approved-linked disease relevance led by influenza. 4 more disease programs remain visible in the same review block.
Start review with influenza because it currently carries approved-linked support. Linked drugs include BALOXAVIR, BALOXAVIR MARBOXIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL16525 | 5.22 | IC50 | 6000.0 | Preclinical |
| CHEMBL16377 | 4.75 | IC50 | 18000.0 | Preclinical |
| CHEMBL277536 | 4.58 | IC50 | 26000.0 | Preclinical |
| CHEMBL16239 | 4.54 | IC50 | 29000.0 | Preclinical |
| CHEMBL275631 | 4.25 | IC50 | 56000.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 2 | 5 | 4.7 |